DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b54312/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q1 2011" report to their offering.
The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry.
BMI has scaled down some of its expectations for full-year 2010 market growth, but retains its essentially bullish forecast of a five-year compound annual growth rate (CAGR) of 14.46% between 2009 and 2014. This trails the 20% plus growth rates seen before 2009, the combination of growth from a higher base and, more ominously, the Russian economys forecast of middling real GDP growth rates compared to other CIS and BRIC peers of under 5%. Nonetheless, BMI currently forecast that the Russian market will increase in value from RUB462.6bn (US$14.6bn) at the end of 2009 to RUR723.5bn (US$28.7bn) by the end of 2014, a near doubling of market value and putting medicines consumption per capita at over US$200.
BMI predict that expanded public coverage will be the key trend in Russia (as in Kazakhstan and possibly Ukraine). In November, Prime Minister Vladimir Putin announced a new implementation date of 2013 for a previously unveiled universal medicines insurance scheme. It was originally due to be implemented in 2010, but appeared to become a casualty of the financial crisis. If realised, the programme promises to raise yet more politically tinged issues regarding pricing, but is still likely to give the market a sharp boost in value. In another positive sign, in September, the government surprised many analysts by pushing through a surprisingly liberal new Law on Medicines after previous drafts threatened onerous legislation on many aspects of pharmaceutical pricing marketing. Most of these were dropped and price setting limited to medicines on the Essential Drug sList the process demonstrated that the Russian government is willing to talk constructively with the industry.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Pharmaceutical Business Environment Ratings
- Russia Market Summary
- Regulatory Regime
- Industry Developments
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Russia Demographic Data
- Methodology
- Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/b54312/russia_pharmaceuti